MIAMI, Jan. 10, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today ...

Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer ...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced its updated strategy for company growth. This comprehensive plan is anchored in three key pillars ...

The investment will be used to help increase enrollment of follicular lymphoma patients in an ongoing Phase I study of Verismo's KIR-CAR therapy.

Sana Biotechnology, Inc. shares surge as a breakthrough in diabetes therapy sparks investor interest. Click for my updated ...

Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer and infectious diseases, today announced an ag ...

German regulatory agency, the Paul Ehrlich Institute, granted approval to expand the INVISE Phase 1 clinical trial evaluating INT2104 for the treatment of B-cell malignancies to Europe The first ...

Cell therapies have suffered from hyped-up expectations, clinical setbacks and high costs. But maybe, just maybe, Arovella is ...

Novel programs will combine validated cell-targeted LNP (ctLNP) delivery with siRNA to selectively modulate T cells in vivoPrograms to focus on ...

WITH cases of flu rising across the UK this winter, personal trainers have shared a quick, 15-minute workout, after research ...

In addition, on January 1, 2025, the Company also received an additional $1.5 million from its $8 million gant from the California Institute for Regenerative Medicines (“CIRM”) that was first ...